中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝硬化肌少症与经颈静脉肝内门体分流术预后的关系

张帮婷 胥莹 杨雪芳 张雪

引用本文:
Citation:

肝硬化肌少症与经颈静脉肝内门体分流术预后的关系

DOI: 10.3969/j.issn.1001-5256.2021.12.041
详细信息
    通信作者:

    胥莹,xuying_0505@163.com

  • 中图分类号: R575.2

Association of sarcopenia with prognosis after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis

  • 摘要: 肌少症是肝硬化患者常见且隐匿的并发症,与肝硬化患者的预后密切相关。经颈静脉肝内门体分流术(TIPS)是治疗肝硬化门静脉高压相关并发症的重要手段。越来越多研究表明,肌少症与TIPS治疗肝硬化门静脉高压的预后有关。就国内外关于肌少症及其与TIPS的相关研究进行综述,以探究二者之间的关系,指导临床治疗。

     

  • [1] KAMIMURA H, SATO T, NATSUI K, et al. Molecular mechanisms and treatment of sarcopenia in liver disease: A review of current knowledge[J]. Int J Mol Sci, 2021, 22(3): 1425. DOI: 10.3390/ijms22031425.
    [2] The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.

    中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
    [3] VIZZUTTI F, SCHEPIS F, ARENA U, et al. Transjugular intrahepatic portosystemic shunt (TIPS): Current indications and strategies to improve the outcomes[J]. Intern Emerg Med, 2020, 15(1): 37-48. DOI: 10.1007/s11739-019-02252-8.
    [4] NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
    [5] PRAKTIKNJO M, CLEES C, PIGLIACELLI A, et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt[J]. Clin Transl Gastroenterol, 2019, 10(4): e00025. DOI: 10.14309/ctg.0000000000000025.
    [6] TSIEN C, SHAH SN, MCCULLOUGH AJ, et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent[J]. Eur J Gastroenterol Hepatol, 2013, 25(1): 85-93. DOI: 10.1097/MEG.0b013e328359a759.
    [7] ARTRU F, MIQUET X, AZAHAF M, et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: A large retrospective CT-based surveillance[J]. Aliment Pharmacol Ther, 2020, 52(9): 1516-1526. DOI: 10.1111/apt.16080.
    [8] ARTRU F, LABREUCHE J, LOUVET A. TIPSS and reversal of sarcopenia, and TIPSS is a promising therapy for sarcopenia in cirrhosis-Authors' reply[J]. Aliment Pharmacol Ther, 2021, 53(1): 211-212. DOI: 10.1111/apt.16152.
    [9] NASEER M, TURSE EP, SYED A, et al. Interventions to improve sarcopenia in cirrhosis: A systematic review[J]. World J Clin Cases, 2019, 7(2): 156-170. DOI: 10.12998/wjcc.v7.i2.156.
    [10] DENT E, MORLEY JE, CRUZ-JENTOFT AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, diagnosis and management[J]. J Nutr Health Aging, 2018, 22(10): 1148-1161. DOI: 10.1007/s12603-018-1139-9.
    [11] PÁR A, HEGYI JP, VÁNCSA S, et al. Sarcopenia - 2021: Pathophysiology, diagnosis, therapy[J]. Orv Hetil, 2021, 162(1): 3-12. DOI: 10.1556/650.2021.32015.
    [12] NISHIKAWA H, FUKUNISHI S, ASAI A, et al. Sarcopenia and frailty in liver cirrhosis[J]. Life (Basel), 2021, 11(5): 399. DOI: 10.3390/life11050399.
    [13] BOJKO M. Causes of sarcopenia in liver cirrhosis[J]. Clin Liver Dis (Hoboken), 2019, 14(5): 167-170. DOI: 10.1002/cld.851.
    [14] WEST J, GOW PJ, TESTRO A, et al. Exercise physiology in cirrhosis and the potential benefits of exercise interventions: A review[J]. J Gastroenterol Hepatol, 2021. DOI: 10.1111/jgh.15474.
    [15] NISHIKAWA H, SHIRAKI M, HIRAMATSU A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria[J]. Hepatol Res, 2016, 46(10): 951-963. DOI: 10.1111/hepr.12774.
    [16] THANDASSERY RB, MONTANO-LOZA AJ. Role of nutrition and muscle in cirrhosis[J]. Curr Treat Options Gastroenterol, 2016, 14(2): 257-273. DOI: 10.1007/s11938-016-0093-z.
    [17] MEYER F, BANNERT K, WIESE M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis[J]. Int J Mol Sci, 2020, 21(15). DOI: 10.3390/ijms21155357.
    [18] HANAI T, SHIRAKI M, MIWA T, et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis[J]. Hepatol Res, 2019, 49(1): 82-95. DOI: 10.1111/hepr.13244.
    [19] SINCLAIR M. Controversies in diagnosing sarcopenia in cirrhosis-moving from research to clinical practice[J]. Nutrients, 2019, 11(10): 2454. DOI: 10.3390/nu11102454.
    [20] ESLAMPARAST T, MONTANO-LOZA AJ, RAMAN M, et al. Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans[J]. Liver Int, 2018, 38(10): 1706-1717. DOI: 10.1111/liv.13876.
    [21] DHALIWAL A, ARMSTRONG MJ. Sarcopenia in cirrhosis: A practical overview[J]. Clin Med (Lond), 2020, 20(5): 489-492. DOI: 10.7861/clinmed.2020-0089.
    [22] WANG Z, LIU FQ. Research advances in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol, 2019, 35(12): 2824-2827. DOI: 10.3969/j.issn.1001-5256.2019.12.040.

    王重, 刘福全. 经颈静脉肝内门体分流术后肝性脑病的研究进展[J]. 临床肝胆病杂志, 2019, 35(12): 2824-2827. DOI: 10.3969/j.issn.1001-5256.2019.12.040.
    [23] PRAKTIKNJO M, BOOK M, LUETKENS J, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis[J]. Hepatology, 2018, 67(3): 1014-1026. DOI: 10.1002/hep.29602.
    [24] GIOIA S, MERLI M, NARDELLI S, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS[J]. Liver Int, 2019, 39(5): 871-877. DOI: 10.1111/liv.14050.
    [25] BENMASSAOUD A, ROCCARINA D, ARICO F, et al. Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites[J]. Am J Gastroenterol, 2020, 115(11): 1911-1914. DOI: 10.14309/ajg.0000000000000959.
    [26] ZOU SL, XU Y. Prognostic evaluation of transjugular intrahepatic portosystemic shunt in treatment of cirrhotic portal hypertension[J]. J Clin Hepatol, 2019, 35(1): 201-204. DOI: 10.3969/j.issn.1001-5256.2019.01.044.

    邹松龙, 胥莹. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症的预后评估[J]. 临床肝胆病杂志, 2019, 35(1): 201-204. DOI: 10.3969/j.issn.1001-5256.2019.01.044.
    [27] MONTANO-LOZA AJ. Clinical relevance of sarcopenia in patients with cirrhosis[J]. World J Gastroenterol, 2014, 20(25): 8061-8071. DOI: 10.3748/wjg.v20.i25.8061.
    [28] SHOREIBAH MG, MAHMOUD K, ABOUELDAHAB NA, et al. Psoas muscle density in combination with model for end-stage liver disease score can improve survival predictability in transjugular intrahepatic portosystemic shunts[J]. J Vasc Interv Radiol, 2019, 30(2): 154-161. DOI: 10.1016/j.jvir.2018.10.006.
    [29] RONALD J, BOZDOGAN E, ZAKI IH, et al. Relative sarcopenia with excess adiposity predicts survival after transjugular intrahepatic portosystemic shunt creation[J]. AJR Am J Roentgenol, 2020, 214(1): 200-205. DOI: 10.2214/AJR.19.21655.
    [30] MONTANO-LOZA AJ, DUARTE-ROJO A, MEZA-JUNCO J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2015, 6: e102. DOI: 10.1038/ctg.2015.31.
    [31] LATTANZI B, NARDELLI S, PIGLIACELLI A, et al. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease[J]. Dig Liver Dis, 2019, 51(11): 1508-1512. DOI: 10.1016/j.dld.2019.09.004.
    [32] SINCLAIR M, CHAPMAN B, HOERMANN R, et al. Handgrip strength adds more prognostic value to the model for end-stage liver disease score than imaging-based measures of muscle mass in men with cirrhosis[J]. Liver Transpl, 2019, 25(10): 1480-1487. DOI: 10.1002/lt.25598.
  • 加载中
计量
  • 文章访问数:  335
  • HTML全文浏览量:  240
  • PDF下载量:  40
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-05-04
  • 录用日期:  2021-05-24
  • 出版日期:  2021-12-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回